Vaxcyte (PCVX) Financial Analysis & Valuation | Quarter Chart
Vaxcyte (PCVX)
PCVXPrice: $61.99
Fair Value: 🔒
🔒score
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pn... more
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to pr... more
Description
Shares
| Market Cap | $8.92B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Grant E. Pickering |
| IPO Date | 2020-06-12 | CAGR | — |
| Employees | 414 | Website | vaxcyte.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PCVX chart loading...
Fundamentals
Technicals
| Enterprise Value | $8.15B | P/E Ratio | -11.01 |
| Forward P/E | -6.37 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 189026970089.88 |
| P/CF Ratio | -1010768805207.87 | P/FCF Ratio | -901950603439.86 |
| EPS | $-5.63 | EPS Growth 1Y | 8.81% |
| EPS Growth 3Y | 68.03% | EPS Growth 5Y | -62.38% |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.21% | ROA | -0.21% |
| ROCE | -0.27% | Current Ratio | 8.83 |
| Quick Ratio | 8.83 | Cash Ratio | 1.41 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | 17.94 | Piotroski Score | 2 |